about
Direct Health Care Cost Utilization in Hong Kong Inflammatory Bowel Disease Patients in the Initial 2 Years Following Diagnosis.Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study.The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection.Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Long Term Outcomes and Predictive Scores for Hepatocellular Carcinoma and HBsAg Seroclearance after HBeAg Seroclearance.Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection-authors' replySerum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infectionA large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearanceModel for End-stage Liver Disease with additional criteria to predict short-term mortality in severe flares of chronic hepatitis BEditorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B?Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year intervalAssociation of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogueHepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinomaEntecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
P50
Q38802004-E089ACBC-0863-40F0-AA0B-CF19934BD9EFQ40096029-D254DD63-0752-47AA-AE8B-51E963E17F88Q40362295-3976C6F6-53BA-4C74-9C1E-A9C4CEE66149Q45326295-0399301B-8D1C-4842-83AC-27558BB0DC1AQ54256777-B9BECB38-A79F-44CF-8B8E-23980248F0BBQ59359598-C25C3BC2-7AB0-4F69-ACC1-3A8047FC9007Q65001476-8E1D4906-CF89-4352-A52E-6F36739BA721Q91173090-B7574D63-6928-4477-A266-A5172417D458Q91391041-B16E4ABB-64E4-4803-9C70-AC0C31FBAB67Q92225365-C01AFF27-006E-49EB-8550-3BA8ECDAFD43Q92348053-F571AD32-C5FB-4686-BF14-F58F57F400AAQ92518178-29F61D42-1F4B-48D7-AE61-01388DF5CE93Q92621523-DFDD43F9-A9BA-40A5-B322-F311E0E513F0Q92659305-1F749F0F-7AEC-423A-989D-BE6F3C02BC8DQ95839572-C8886DAE-2C0F-462C-9098-EAAD0995515B
P50
description
researcher
@en
wetenschapper
@nl
name
Lung-Yi Mak
@en
Lung-Yi Mak
@nl
type
label
Lung-Yi Mak
@en
Lung-Yi Mak
@nl
prefLabel
Lung-Yi Mak
@en
Lung-Yi Mak
@nl
P31
P496
0000-0002-2266-3935